Royalty Report: Drugs, Cancer, Disease – Collection: 271809

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 18

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 18

Primary Industries

  • Drugs
  • Cancer
  • Disease
  • Pharmaceuticals
  • Therapeutic
  • Diagnostic
  • Biotechnology
  • Antibody
  • Genome
  • cell therapy

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 271809

License Grant
The Licensor of Denmark grants an exclusive development, manufacturing and commercialization is a global license for daratumumab.
License Property
Daratumumab, marketed as DARZALEX, is a human IgG1k monoclonal antibody, or mAb, that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of MM cells.
Field of Use
Daratumumab is for the Treatment of Multiple Myeloma.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.

IPSCIO Record ID: 3283

License Grant
The University hereby grants the Licensee an exclusive worldwide right and license in the Licensed field to practice under the Patent Rights and the Technology Rights and to make, have made, use, offer for sale, sell and import Licensed products or the practice of services utilizing the Licensed Processes. Licensee shall have an exclusive option to license any Invention. Licensee
shall have the right to grant sublicenses consistent with this Agreement.
License Property
United States Patent   7,668,659
Diagnosis and classification of multiple myeloma

United States Patent   7,308,364
Diagnosis of multiple myeloma on gene expression profiling

Field of Use
Licensed Field shall mean those applications of Patent Rights and/or the Technology Rights with respect to non-malignant and malignant human or animal pathologies, including but not limited to, determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient, susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen.

IPSCIO Record ID: 26487

License Grant
The Licensor hereby grants to Switzerland company an exclusive (including as to Licensor and its Affiliates) royalty-bearing license to register, distribute, market, use and sell the Products in the Territory under the Licensor'd Patent Rights and the Licensor's Technology.
License Property
Products shall mean each article of manufacture, substance, material, chemical, formulation or composition which is or includes Thalidomide as an active ingredient, including, without limitation, any composition that comprises Thalidomide and a non-steroidal anti-inflammatory compound(s).

The term Products expressly excludes Thalidomide analogs.  The product is currently is under review by the European Medicines Agency (EMEA) to treat patients with newly diagnosed multiple myeloma.  Multiple myeloma (also known as MM, myeloma, plasma cell myeloma, or as Kahler's disease after Otto Kahler) is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies. Myeloma is regarded as incurable, but remissions may be induced with steroids, chemotherapy, thalidomide and stem cell transplants. Myeloma is part of the broad group of diseases called hematological malignancies.

IPSCIO Record ID: 70123

License Grant
The company acquired the rights to develop rHuEPO for the treatment of multiple myeloma under a research and license agreement with two other parties, one is an Israeli Licensor, the technology transfer company of the University.
License Property
rHuEPO which stands for recombinant human erythropoietin, is a hormone, produced by the kidneys, and is responsible for red blood cell production in bone marrow.

Multiple Myeloma is a severe and incurable malignant hematological cancer of plasma cells.

Field of Use
This agreement pertains to the drug industry relating to the treatment of multiple myeloma.

We were granted an Orphan-drug designation from the FDA in May 2011, for rHuEPO.

IPSCIO Record ID: 226067

License Grant
Licensor hereby grants to Company an exclusive license (with the right to grant sublicenses) under the Licensed IP Rights to conduct research and to develop, make, have made, use, offer for sale, sell and import Products in the Territory for use in the Field.
License Property
'Technology' shall mean compounds and uses for treating p62 mediated diseases as described in the Licensed IP Rights.

LICENSED  PATENT RIGHTS
1. PCT/US2012/049911 (WO2013022919A1)
2. USSN 61/521,287
3. USSN 14/237,494
4. Chinese Patent Application No. 201280048718; Pre-grant Publ. No. 103930166

ASSIGNMENT DOCUMENTS
1. Assignment document from University of Pittsburgh to inventors (Patent family of USSN 14/237,494).
2. Assignment document from Inventors to Dr. Xiang-Qun Xie (Patent family of USSN 14/237,494) .
3. Assignment document from Dr. Xiang-Qun Xie to ID4Pharma, LLC (Patent family of USSN 14/237,494).

Licensor have developed novel chemical compounds (e.g., OXS-4235) which inhibit osteoclastic bone destruction in multiple myeloma.

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.

The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma.

Field of Use
'Field' shall mean compounds and methods for detection, diagnosis, prognosis, monitoring or predisposition testing of any disease, state or condition in humans or other animals.

IPSCIO Record ID: 275366

License Grant
Licensor of Denmark grants Licensor of Switzerland. the remaining rights to ofatumumab.

The product, Ofatumumab, is being commercialized by Licensee.

License Property
The Product, ofatumumab, is marketed as Arzerra for certain indications of chronic lymphocytic leukemia (CLL).

Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).

Field of Use
Ofatumumab for the treatment of cancer and also for non-cancer treatments.  Ofatumumab, previously approved for certain CLL indications, is in pivotal Phase III testing by Licensee for the treatment of RMS, with the Phase III ASCLEPIOS I and II studies.

IPSCIO Record ID: 246304

License Grant
Within this license agreement, the terms of another agreement between the parties are modified.  In the modified agreement, the Parties agreed to the development of anti-CD40 antibodies.  The modified agreement is non-exclusive.
License Property
The modified agreement is for antibody products that bind to the CD40 antigen.

GN-40 is a humanized monoclonal antibody that targets the CD40 antigen, which is highly expressed on most B lineage hematologic malignancies including non-Hodgkin's lymphoma, multiple myeloma and chronic lymphocytic leukemia. CD40 is also found on many types of solid tumors, including bladder, renal and ovarian cancer, and may play a role in immunologic diseases.

Field of Use
The Field of Use shall mean any human use.

SGN-40 is a humanized monoclonal antibody currently in Phase I and Phase II clinical trials for multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin's lymphoma.

IPSCIO Record ID: 332224

License Grant
Licensor of Israel grants the exclusive right and license, including the right, subject to the Consent Agreement, to sublicense, under the Licensor Technology and Trademarks to Obtain Regulatory Approval, make, have made, use, promote, market, sell, have sold, offer to sell, import or export Products in the Territory.

Licensor grants an exclusive license under its entire right, title and interest in and to the Licensor Trademarks, if any, to use and display the Licensor Trademarks in connection with the Commercialization of Product within the Territory.

This agreement includes a non-exclusive grant back from Licensee to Licensor.

License Property
The trademark is HEPEX.

The patents include Human Monoclonal Antibody Against Hepatitis. B Surface Antigen {HBVSAG), and, Treatment of hepatitis B virus infection with human  monoclonal antibodies.

Additional HBV Products shall mean any and all compounds, products, methods or systems, other than a Product or a Directly Competitive Product, in any formulation for the treatment or prevention of Hepatitis 8, that is Controlled by Licensor as of the Effective Date or at any time during the term of this Agreement.

HB/g shall mean the immunoglobulin product containing polyclonal antibodies (derived from human plasma) to hepatitis B surface antigen, and occasionally referred to as HBlg.

HBV Antibody shall mean any and all human or humanized monoclonal immunoglobulins, including intact immunoglobulin molecules and any portion or fragment of an immunoglobulin molecule, such as those portions or fragments commonly known as Fab, Fab, F(ab)2 and F(v), that is directed to and binds to the Hepatitis B virus or any portion of the Hepatitis 8 virus.

HepeX-8 shall mean, without regard to the actual trade name used, any Product containing the human monoclonal antibody [17;1.41., as referred to and described in ECACC Accession No; 96()521.69], and the human monoclonal antibody [19.79.s,; as referred to and described in ECACC Accession No. 96052168], and no other antibodies or fragments of other antibodies.

Field of Use
The field is for use against Hepatitis B.

IPSCIO Record ID: 27543

License Grant
Licensor hereby grants to Company an exclusive license (with the right to grant sublicenses) under the Licensed IP Rights to conduct research and to develop,  make, have made, use,  offer for sale, sell and import Products in the Territory for use in the Field.

Licensor grants to Company the right to grant sublicenses to third parties, provided that (i) the Sublicensee agrees to abide by all the terms and provisions of this Agreement; (ii) Company remains fully liable for the performance of its and its Sublicensee's obligations hereunder; and (iii) Company notifies Licensor of any grant of a sublicense and provide to Licensor upon Licensor request a copy of any sublicense agreement.

License Property
Technology shall mean compounds and uses for treating p62 mediated diseases as described in the Licensed IP Rights.

Licensed Patent Rights
1. PCT/US2012/049911 (WO2013022919A1)
2. USSN 61/521,287
3. USSN 14/237,494
4. Chinese Patent Application No. 201280048718; Pre-grant Publ. No. 103930166

ASSIGNMENT DOCUMENTS
1. Assignment document from University of Pittsburgh to inventors (Patent family of USSN 14/237,494).
2. Assignment document from Inventors to Dr. Xiang-Qun Xie (Patent family of USSN 14/237,494) .
3. Assignment document from Dr. Xiang-Qun Xie to ID4Pharma, LLC (Patent family of USSN 14/237,494).

Licensor have developed novel chemical compounds (e.g., OXS-4235) which inhibit osteoclastic bone destruction in multiple myeloma.

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies.

The drug is a P62-ZZ chemical inhibitor intended for use as a treatment for multiple myeloma.

Field of Use
'Field' shall mean compounds and methods for detection, diagnosis, prognosis, monitoring or predisposition testing of any disease, state or condition in humans or other animals..

The Licensee's leading drug candidate is a small molecule therapeutic targeting the treatment of multiple myeloma and associated osteolytic lesions.

IPSCIO Record ID: 203353

License Grant
This agreement is for Collaborative Research. The goal of the Program is to humanize and optimize Candidate Molecules.  The plan includes antibody cloning, assay development and validation, design and synthesis of Humanization/Optimization Libraries, Screening, Characterization, Affinity Maturation, Iterative Affinity Maturation and Deliverables.

Licensor shall optimize and humanize the Candidate Molecules as set forth in the Research Plan. Licensor shall use its commercially reasonable efforts to perform its obligations under the Program in accordance with the Research Plan. Licensor shall provide the personnel, materials, equipment and other resources required to conduct its obligations under the Program. Licensor shall perform its obligations under the Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of applicable laws and regulations.

Licensee shall use its best efforts to actively research, develop and obtain regulatory approvals to market in major markets throughout the world at least one Product.

License Property
Product shall mean any product for use in the Field, which is a composition that incorporates one or more Program Antibodies or is derived from one or more Program Antibodies.

The Candidate Molecules shall mean, collectively, monoclonal antibody (mAb) HUIV26 and mAb HUI77 as provided by Licensee to Licensor.

Materials shall mean the Candidate Molecules, DNA sequence information and the cDNA to encode Candidate Molecules and the hybridoma cell lines expressing the Candidate Molecules.

Program Antibody shall mean the optimized and humanized compositions of matter developed under the Program, and the cDNA encoding such compositions of matter, delivered to Licensee.

Licensor utilizes its technology to humanize a murine monoclonal antibody, which is now referred to as D93, and another of our anti-angiogenic monoclonal antibodies.

Field of Use
The Field shall mean human and veterinary therapeutic and diagnostic applications.

D93 is humanized, anti-angiogenic monoclonal antibody, in patients with solid tumors.

IPSCIO Record ID: 274811

License Grant
The Licensor of Denmark grants an exclusive worldwide license and option agreement to develop and commercialize HexaBody-CD38.

Licensee may exercise its option and receive a worldwide exclusive license to certain intellectual property and an exclusive sublicense to certain intellectual property that Licensor has licensed from third parties, in each case, to develop, manufacture and commercialize HexaBody-CD38.

License Property
HexaBody-CD38, a next-generation human CD38 mAb product incorporating the proprietary HexaBody technology.
Field of Use
The field of use is to fund research and development activities until completion of clinical proof of concept studies in multiple myeloma and diffuse large B-cell lymphoma.

IPSCIO Record ID: 29196

License Grant
University hereby grants a worldwide exclusive license under the Licensed Technology, to develop, manufacture, have manufactured, use, market, import, have imported, offer for sale and sell Licensed Products.
License Property
“Licensed Products” shall mean all products derived from a combination of LYM-1 antibody or LYM-2 antibody plus the radioactive Iodine 131 combination.

United States Patent 4,724,213 issued February 9, 1988; Epstein, “Murine Hybridoma LYM-1 and Diagnostic Antibody Produced Thereby.”  United States Patent 4,724,212 issued February 9, 1988; Epstein, “Murine Hybridoma LYM-2 and Diagnostic Antibody Produced Thereby.”

“Hybridoma 173-9, Lym-1” (NU 8314-A)    A hybridoma clone, designated Lym-1, was produced from the fusion of primed mouse splenocytes and mouse myeloma NS-a cells. Hybridoma Lym-1 produced a murine IgG2a monoclonal antibody which recognizes a 31, 32, 33 and 35 kilodalton cell surface protein expressed in normal and malignant B lymphocytes.  Immunoperoxidase staining of a panel of normal human tissues shows that Lym-1 reacts with germinal center and mantle zone B lymphocytes and interdigitating histiocytes of the lymph node, medullary dendritic cells of the thymus, and weakly with surface epithlium of the colon. A subset of peripheral blood B cells are positive and no reactivity has been observed in human bone marrow by flow cytometric analysis. The antigen recognized by Lym-1 is not shed from the surface of lymphoma cells either in cell culture or in patients and is not modulated after Lym-1 binding. Lym-1 itself has been shown to have high avidity to human lymphoma cells IN VIVO as demonstrated by radionuclide binding studies in lymphoma patients using I-123 conjugates. Binding to normal tissues such as the bone marrow, spleen, lymph node, liver, kidney, lung or central nervous system has not been demonstrated in over 30 patients studied. Lym-1 has further been found to be highly stable to radionuclide conjugation methods and may be prepared as F(ab1)2 or F(ab) fragments without significant loss of antibody activity. Collectively, these data suggest that Lym-1 will be an appropriate reagent for IN VIVO diagnosis and therapy of the human B-cell lymphomas and leukemias.

'Hybridoma Clone 1010-9, Lym-2” (NU 8314-B) A hybridoma clone, designated Lym-2, was produced from the fusion of primed mouse splenocytes and mouse myeloma NS-1 cells. Hybridoma Lym-2 produced a murine IgG1 monoclonal antibody which recognizes a cell surface protein expressed in normal and malignant B lymphocytes. Immunoperoxidase staining of a panel of normal human tissues show that Pym-2 reacts with germinal center and mantle zone B lymphocytes and interdigitating histiocytes of the lymph node. A subset of peripheral blood B cells are positive and no reactivity has been observed in human bone marrow by flow cytometric analysis. Because of the remarkable specificity of Lym-2 for human B-cells and derived malignancies, these data suggest that Lym-2 will be appropriate for reagent for in vivo diagnostic and therapy of the human B-cell lymphomas and leukemias.

“Hybridoma Clone 818-18, BM-1” (NU 8216-C)  A hybridoma clone, designated 818-18, was produced from the fusion of primed mouse splenocytes and mouse myeloma NS-1 cells. Clone 818-18 produces a murine IgG1 monoclonal antibody which recognizes a nuclear antigen expressed in human granulocytes and myeloid precursors and acute and chronic myeloid leukemia. Immunoperoxidase staining with 818-18 on B5 fixed, paraffin embedded clot preparations of bone marrow aspirates shows positive nuclear staining of myeloid cells with normal non-specific background staining. The remarkable specificity of this reagent and its ability to stain B5 fixed, paraffin embedded tissues makes it a unique reagent for the diagnosis of myeloid derived leukemias.

Field of Use
Oncolym(R) was in a Phase II/III clinical trial for the treatment of non-Hodgkin's B-cell Lymphoma.

IPSCIO Record ID: 3921

License Grant
The Israel Pharma Licensee announced that it has entered into an asset purchase Agreement with the Israel Pharma Licensor for the rights to a use patent on Recombinant Erythropoietin for the prolongation of multiple myeloma MM patients' survival and improvement of their quality of life.

MM is a severe plasma cell malignancy characterized by the accumulation and proliferation of clonal plasma cells in the marrow, leading to the gradual replacement of normal hematopoiesis.

Field of Use
The rights granted apply to the healthcare industry.

IPSCIO Record ID: 307594

License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.

The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.

Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.

Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.

Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.

IPSCIO Record ID: 28127

License Grant
The Licensee entered into an exclusive collaboration Agreement with the Licensor, for the development and commercialisation of MEDI4736 across a range of blood cancers including non-Hodgkin''s lymphoma, myelodysplastic syndromes and multiple myeloma.
License Property
MEDI4736 is an investigational human monoclonal antibody directed against programmed cell death ligand 1 (PD-L1). Signals from PD-L1 help tumours avoid detection by the immune system. MEDI4736 blocks these signals, countering the tumour's immune-evading tactics. MEDI4736 was accelerated into Phase III clinical development in non-small cell lung cancer and head and neck cancer. The Licensor will also be responsible for global commercialisation of approved treatments.
Field of Use
The Licensee will manufacture and book all sales of MEDI4736 and will pay a royalty to the Licensor on worldwide sales in haematological indications.

IPSCIO Record ID: 256278

License Grant
On the Effective Date the Parties have terminated a certain Collaboration Agreement, and with this agreement, the Parties desire to reallocate the rights and responsibilities of the Parties with respect to further research and development of the GM-CSF Target.

Licensor grants to Licensee of Germany an exclusive, worldwide, license under the Licensor Licensed Technology to Exploit Licensed Products.

Licensor grants a worldwide, non-exclusive, perpetual, irrevocable and non-terminable license under the Collaboration Patents, as defined in the Collaboration Agreement, with the right to grant and authorize the grant of sublicenses, to Exploit Licensed Products.

License Property
BiTE Product means any composition or formulation consisting of or comprising a bi-specific Single Chain Antibody expressed as a single polypeptide chain, binding to T-cells.

GM-CSF Target means the whole or part of the human granulocyte macrophage-colony stimulating factor identified by the SWISS-PROT entry name CSF2 HUMAN and accession number P0414 l.

Single-Chain Antibodies
Antibodies are proteins produced by the body's immune system in response to the presence of antigens, such as bacteria, viruses or other disease causing agents. Antibodies of identical molecular structure that bind to a specific target are called monoclonal antibodies. Single-chain antibodies are genetically engineered antibodies that incorporate only the antigen binding domains of an antibody. Thus, SCAs have the binding specificity and affinity of monoclonal antibodies; however, in their native form they are only one-fifth to one-sixth the size of a monoclonal. The small size of SCAs typically gives them shorter half-lives than monoclonal antibodies, making them better suited for use in acute indications or in other indications where the large size of a monoclonal antibody would inhibit the compound from reaching the area of potential therapeutic activity. In addition, SCAs are a well-established discovery format-of-choice in generating antibodies from phage or yeast display libraries.

Field of Use
The field for Patent 5,223,409 is solely in the field of manufacture, use or sale of Single Chain Antibodies.

The field of use for this agreement otherwise is limited to not include the right to exploit the Products for Radioimmunoguided Surgery(TM), Reagents and kits in the research market for production and cloning of genes encoding Single Chain Antibodies and their fusions in a filamentous bacteriophage-derived vector system, and for expression and screening of Single Chain Antibodies fused with the minor coat protein or attachment or adsorption protein of filamentous bacteriophage, and, Single Chain Antibodies fused with, or for the assay or purification of, Tumor Necrosis l Factor alpha (TNF-a.) or Lymphotoxin.

Products for Radioimmunoguided SurgeryTM (RIGS'), in which a radiolabelled Single Chain Antibody is administered to a cancer patient; time elapses for preferential concentration of the radiolabelled Single Chain Antibody in neoplastic tissue and decrease of background radioactivity in the patient; and such preferentially concentrated radiolabelled Single Chain Antibody is detected within a surgical operative field by a detector probe placed in juxtaposition with tissue suspected of containing said radiolabelled Single Chain Antibody.

IPSCIO Record ID: 369364

License Grant
In consideration of the mutual covenants contained in this Amendment and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree to amend several sections including but not limited to Royalties and Licensee shall have the right, at its sole discretion, either itself or through counsel  of its choice, to control the preparation, filing, prosecution, maintenance and enforcement of all Patents which claim Program Antibodies.
License Property
This agreement is for Collaborative Research. The goal of the Program is to humanize and optimize Candidate Molecules. The plan includes antibody cloning, assay development and validation, design and synthesis of Humanization/Optimization Libraries, Screening, Characterization, Affinity Maturation, Iterative Affinity Maturation and Deliverables. Licensor shall optimize and humanize the Candidate Molecules as set forth in the Research Plan. Licensor shall use its commercially reasonable efforts to perform its obligations under the Program in accordance with the Research Plan. Licensor shall provide the personnel, materials, equipment and other resources required to conduct its obligations under the Program. Licensor shall perform its obligations under the Program in accordance with high scientific and professional standards, and in compliance in all material respects with the requirements of applicable laws and regulations. Licensee shall use its best efforts to actively research, develop and obtain regulatory approvals to market in major markets throughout the world at least one Product.

Product shall mean any product for use in the Field, which is a composition that incorporates one or more Program Antibodies or is derived from one or more Program Antibodies. The Candidate Molecules shall mean, collectively, monoclonal antibody (mAb) HUIV26 and mAb HUI77 as provided by Licensee to Licensor. Materials shall mean the Candidate Molecules, DNA sequence information and the cDNA to encode Candidate Molecules and the hybridoma cell lines expressing the Candidate Molecules. Program Antibody shall mean the optimized and humanized compositions of matter developed under the Program, and the cDNA encoding such compositions of matter, delivered to Licensee.

Field of Use
HUI77 and HUIV26 are anti-angiogenic mouse antibodies discovered using subtractive immunization, which could enable Licensee to pursue the commercialization of these antibodies.

Licensee is developing a family of antibodies that is selective for angiogenesis.  Anti-angiogenesis as a treatment for cancer.

IPSCIO Record ID: 332232

License Grant
Licensed Patents. Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under the Licensed Patents, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

Know-How License Licensor hereby grants to Licensee an exclusive, nontransferable (except with respect to the assignment provision in this Agreement) license during the Term under Licensor’s rights in and to the Captisol Data Package and Product Know-How, solely to research, develop, make, have made, import, use, offer for sale and sell the Licensed Product in the Territory in the Field.

License Property
Captisol means Captisol®, also known scientifically as sulfobutylether ß(beta) cyclodextrin, sodium salt, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Serial Number 12/790,724

Compound means that certain pharmaceutical compound known as melphalan, including all of its optical isomers, and salt, ester, and polymorphic forms.

US Patent #5,376,645 – Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US Patent #7,629,331 – Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
US Patent #7,635,773 – Sulfoalkyl ether cyclodextrin compositions

Field of Use
The Captisol-enabled melphalan product candidate is currently in a pivotal trial being conducted by Ligand for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma.
Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help you fight infections by making antibodies that recognize and attack germs. In multiple myeloma, cancerous plasma cells accumulate in the bone marrow and crowd out healthy blood cells.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.